U.S. MARKETS FOR APHERESIS, HEMOSTASIS, AND STEM CELL THERAPY PRODUCTS

261 Pages | 62 Exhibits | 2002 Analysis | Forecasts Through 2007

OVERVIEW:
In 2001, the U.S. apheresis, hemostasis, and stem cell therapy products market totaled $580.2 million, a figure that is expected to more than double over the forecast period covered by this report. Technologies such as blood modification, salvaging, and substitution; stem cell expansion and transplantation; and therapeutic apheresis will drive market growth.

This report from Medtech Insight presents a detailed overview of apheresis, hemostasis, and stem cell therapy technologies and markets, along with 15 company profiles.

Major topics include: donor apheresis; therapeutic apheresis; blood disorders; metabolic disorders; blood substitutes; blood transfusions; plasma volume replacement; blood modifiers; blood salvaging; stem cell transplantations; stem cell expansion ex vivo; and umbilical cord blood collection.

TABLE OF CONTENTS:
EXECUTIVE SUMMARY

i. Introduction
ii. Scope and Methodology
iii. The Apheresis Products Market
iv. The Hemostasis Products Market
v. The Stem Cell Therapy Products Market
vi. Total Market Forecast

Exhibit ES-1: Advantages and Disadvantages of Apheresis Platelets
Exhibit ES-2: Apheresis Equipment and Disposables, Market Forecast, 2001-2007
Exhibit ES-3: Blood Demand, by Condition/Procedure
Exhibit ES-4: Hemostasis Products, Market Forecast, 2001-2007
Exhibit ES-5: Advantages and Disadvantages of Stem Cells, by Source
Exhibit ES-6: Stem Cell Therapy Products, Market Forecast, 2001-2007
Exhibit ES-7: Apheresis, Hemostasis, and Stem Cell Therapy Products, Market Forecast, 2002 and 2007

1. APHERESIS PRODUCTS MARKET

1.1 Apheresis
	1.1.1 Donor Apheresis
	1.1.2 Therapeutic Apheresis
1.2 Apheresis Applications
	1.2.1 Platelet Therapy
	1.2.2 Plasmapheresis
	1.2.3 Erythrocytapheresis
	1.2.4 Leukoreduction
1.3 Safety
1.4 Costs
1.5 Disadvantages of Single-Donor Collections
1.6 Therapeutic Apheresis
	1.6.1 Types
		1.6.1.1 Cytapheresis
		1.6.1.2 Erythrocytapheresis
		1.6.1.3 Extracorporeal Photophoresis
			1.6.1.3.1 Development
			1.6.1.3.2 Technique
			1.6.1.3.3 Current and Developing Indications
		1.6.1.4 Leukapheresis
		1.6.1.5 Plasmapheresis
		1.6.1.6 Therapeutic Phlebotomy
		1.6.1.7 Thrombocytapheresis
	1.6.2 Indications and Protocols
		1.6.2.1 Neurologic Conditions
			1.6.2.1.1 Amyotrophic Lateral Sclerosis
			1.6.2.1.2 Chronic Inflammatory Demyelinating Polyneuropathy
			1.6.2.1.3 Guillain-B 1.6.2.1.4 Multiple Sclerosis
			1.6.2.1.4 Myasthenia Gravis
		1.6.2.2 Blood Disorders
			1.6.2.2.1 Autoimmune Hemolytic Anemia
			1.6.2.2.2 Cutaneous T-Cell Lymphoma
			1.6.2.2.3 Hematologic Malignancy
			1.6.2.2.4 Hemolytic Uremic Syndrome
			1.6.2.2.5 Hemophilia
			1.6.2.2.6 Idiopathic Thrombocytopenia Purpura
			1.6.2.2.7 Neonatal Hemolytic Disease
			1.6.2.2.8 Paraproteinemia
			1.6.2.2.9 Sickle Cell Anemia
			1.6.2.2.10 Thrombotic Thrombocytopenia Purpura
		1.6.2.3 Renal Disease
			1.6.2.3.1 Goodpasture's Syndrome
			1.6.2.3.2 Immune-Complex Nephritis
			1.6.2.3.3 Renal Transplantation
		1.6.2.4 Rheumatic Disease
			1.6.2.4.1 Systemic Lupus Erythematosus
			1.6.2.4.2 Rheumatoid Arthritis
			1.6.2.4.3 Inflammatory Myositis
		1.6.2.5 Metabolic Disorders
			1.6.2.5.1 Hyperlipidemia
			1.6.2.5.2 Refsum's Disease
			1.6.2.5.3 Age-Related Macular Degeneration
	1.6.3 Reimbursement
1.7 Products
	1.7.1 Current Equipment Technology
		1.7.1.1 Centrifugation Systems
		1.7.1.2 Membrane Filtration Systems
	1.7.2 Technological Developments
	1.7.2.1 Adsorption Devices
	1.7.2.2 Elutriation Systems
	1.7.2.3 Ultrafiltration
1.8 Trends in Apheresis Procedures
	1.8.1 Donor Apheresis
	1.8.2 Therapeutic Apheresis
1.9 Market Forecast
1.10 Market Analysis

Exhibit 1-1: Whole-Blood Platelets Versus Apheresis Platelets
Exhibit 1-2: Advantages and Disadvantages of Apheresis Platelets
Exhibit 1-3: Leukoreduced Blood Products, Cost Forecast, 2001-2007
Exhibit 1-4: 2001, Blood Product Reimbursement Rates
Exhibit 1-5: Procedure Times for Manual and Apheresis Blood Collection Procedures
Exhibit 1-6: Apheresis Donation Interval Guidelines
Exhibit 1-7: Goals of Therapeutic Apheresis, by Type
Exhibit 1-8: Therapeutic Apheresis Categories
Exhibit 1-9: Guidelines for Therapeutic Apheresis, by Disease
Exhibit 1-10: Apheresis Recommendations for Neurologic Conditions
Exhibit 1-11: 2001, United States Patient Registrants for Kidney and Kidney-Pancreas Transplants
Exhibit 1-12: 2001, Kidney and Kidney-Pancreas Transplantation Survival Rates
Exhibit 1-13: Therapeutic Apheresis Indications Covered by Medicare
Exhibit 1-14: 2002, Apheresis Centrifugation Systems
Exhibit 1-15: 2002, Hollow-Fiber Membrane Filtration Systems
Exhibit 1-16: Therapeutic Apheresis Systems, by Technique
Exhibit 1-17: Apheresis, Procedure Volumes Forecast, by Type, 2001-2007
Exhibit 1-18: Donor Apheresis, Procedure Volumes Forecast, 2001-2007
Exhibit 1-19: Therapeutic Apheresis, Procedure Volumes Forecast, 2001-2007
Exhibit 1-20: Apheresis Equipment and Disposables, Market Forecast, 2001-2007
Exhibit 1-21: 2001, Apheresis Equipment and Disposables Market, Share by Supplier

2. THE HEMOSTASIS PRODUCTS MARKET

2.1 Blood Supply
	2.1.1 Paid Donors
	2.1.2 Blood Safety
		2.1.2.1 Products
2.2 Blood Components
	2.2.1 Whole Blood
	2.2.2 Red Blood Cells
	2.2.3 Platelets
		2.2.3.1 Supply
	2.2.4 Plasma
	2.2.5 Human Serum Albumin
	2.2.6 Human Immunoglobulin
	2.2.7 Cryoprecipitate/Coagulation Factors
2.3 Blood Collection
2.4 Blood Transfusions
	2.4.1 Autotransfusion
	2.4.2 Number of Transfusions
	2.4.3 Surgery and Transfusions
	2.4.4 Blood Screening
2.5 Blood Substitutes
	2.5.1 Blood Substitute Technology
	2.5.2 Products in Development
		2.5.2.1 Alliance Pharmaceutical
		2.5.2.2 Baxter International
		2.5.2.3 Biopure
		2.5.2.4 Enzon
		2.5.2.5 Hemosol
		2.5.2.6 Northfield Laboratories
		2.5.2.7 Sonus Pharmaceuticals
		2.5.2.8 Synthetic Blood International
	2.5.3 Market Forecast
2.6 Plasma Volume Replacement Products
	2.6.1 Colloid Solutions
		2.6.1.1 Albumin
		2.6.1.2 Dextran
		2.6.1.3 Gelatin
		2.6.1.4 Hydroxyethyl Starch
		2.6.1.5 Plasma Protein Fraction
	2.6.2 Crystalloid Solutions
		2.6.2.1 Dextrose Solution
		2.6.2.2 Hartmann's Solution
		2.6.2.3 Normal Saline
	2.6.3 Guidelines
	2.6.4 Manufacturers
		2.6.4.1 Abbott Laboratories
		2.6.4.2 Instituto Grifols
		2.6.4.3 ZLB BioPlasma/CSL
	2.6.5 Recombinant Human Serum Albumin
	2.6.6 Market Forecast
2.7 Blood Modifiers
	2.7.1 Anticoagulants
		2.7.1.1 Heparin
		2.7.1.1.1 Indications
		2.7.1.2 Warfarin
			2.7.1.2.1 Indications
		2.7.1.3 Anticoagulant Products
	2.7.2 Hemophilia
		2.7.2.1 Treatment
		2.7.2.2 Factor VIII Inhibitors
		2.7.2.3 Factor VIII
		2.7.2.4 Recombinant Factor VIII
		2.7.2.5 Factor IX
		2.7.2.6 Factor VIIa
	2.7.3 Antiplatelet Agents
		2.7.3.1 Plavix
		2.7.3.2 Persantine
		2.7.3.3 Ticlid
		2.7.3.4 ReoPro
		2.7.3.5 Aggrastat
		2.7.3.6 Integrilin
	2.7.4 Colony Stimulating Factor
		2.7.4.1 Neutropenia
		2.7.4.2 Colony Stimulating Factor Agents
	2.7.5 Hematinic Agents
		2.7.5.1 Cyanocobalamin
		2.7.5.2 Anabolic Steroids
		2.7.5.3 Folates
		2.7.5.4 Iron
		2.7.5.5 Erythropoietin
		2.7.5.6 Thrombopoietin Growth Factor
	2.7.6 Immunoglobulins
		2.7.6.1 Costs
		2.7.6.2 Shortages
	2.7.7 Hemorheologic Agents
		2.7.7.1 Treatment
		2.7.7.2 Treatment Agents
	2.7.8 Hemostatics and Antifibrinolytic Agents
		2.7.8.1 Antifibrinolytic Amino Acids
		2.7.8.2 Desmopressin
		2.7.8.3 Aprotinin
	2.7.9 Thrombolytic Agents
		2.7.9.1 Streptokinase
		2.7.9.2 Urokinase
		2.7.9.3 Tissue Plasminogen Activator
			2.7.9.3.1 Disadvantages
	2.7.10 Vitamin K
	2.7.11 Market Analysis
	2.7.12 Market Forecast
2.8 Blood Salvaging
	2.8.1 Technology
	2.8.2 Applications
	2.8.3 Risks
	2.8.4 Products
	2.8.5 Market Forecast

Exhibit 2-1: Blood Demand, by Condition/Procedure
Exhibit 2-2: Recommendations For Use of Immunoglobulin Intravenous, by Source
Exhibit 2-3: Blood Collection, Procedure Volumes Forecast, 2001-2007
Exhibit 2-4: Blood Transfusion, Procedure Volumes Forecast, 2001-2007
Exhibit 2-5: 2002, Selected Blood Substitute Products
Exhibit 2-6: Blood Substitute Products, Market Forecast, 2001-2007
Exhibit 2-7: 2001, Blood Substitution Incidence, by Condition
Exhibit 2-8: 2002, Selected Plasma Volume Replacement Products, by Indication
Exhibit 2-9: 2002, Selected Plasma Volume Expanders
Exhibit 2-10: Plasma Volume Replacement Products, Market Forecast, 2001-2007
Exhibit 2-11: 2002, Indications for Heparin Therapy
Exhibit 2-12: Indications for Warfarin Therapy
Exhibit 2-13: 2002, Selected Factor VIII Products
Exhibit 2-14: 2002, Selected Factor IX Products
Exhibit 2-15: 2002, Selected Antiplatelet Agents
Exhibit 2-16: 2002, Advantages of Plavix
Exhibit 2-17: 2002, Populations at Risk for Developing Neutropenia
Exhibit 2-18: 2002, Selected Immunoglobulin Intravenous Products
Exhibit 2-19: Risk Factors for Peripheral Artery Disease
Exhibit 2-20: Indications for Antifibrinolytic Therapy
Exhibit 2-21: Indications for Desmopressin Therapy
Exhibit 2-22: Indications for Thrombolytic Agent Therapy
Exhibit 2-23: 2001, Blood Modifiers Market, Share by Supplier
Exhibit 2-24: Blood Modifiers, Market Forecast, 2001-2007
Exhibit 2-25: Selected Surgical Applications for Blood Salvaging
Exhibit 2-26: Blood Salvaging Products, Market Forecast, 2001-2007

3. THE STEM CELL THERAPY PRODUCTS MARKET

3.1 Sources and Types of Stem Cells
3.2 Blood Cell Formation
	3.2.1 Embryonic Stem Cells
		3.2.1.1 Federal Funding
3.3 Stem Cell Transplantations
	3.3.1 Bone Marrow Transplantations
		3.3.1.1 Limitations
	3.3.2 Peripheral Blood Stem Cell Transplantation
		3.3.2.1 Advantages and Disadvantages
		3.3.2.2 Collection, Storage, and Preparation
		3.3.2.3 Mobilized Peripheral Blood
		3.3.2.4 Infusion
	3.3.3 Umbilical Cord Blood Transplantations
3.4 Stem Cell Selection and Cell Purging
	3.4.1 Depletion Strategies
	3.4.2 Positive Selection Techniques
	3.4.3 Clinical Outcomes
3.5 Stem Cell Therapies
	3.5.1 Cancer
		3.5.1.1 Breast Cancer
	3.5.2 Genetic Disorders
	3.5.3 Heart Disease
	3.5.4 Diabetes
	3.5.5 Autoimmune Disorders
	3.5.6 Immunodeficiencies
	3.5.7 Diagnosis and Immunization
	3.5.8 Organ Transplantation
		3.5.8.1 Xenotransplantation
			3.5.8.1.1 Limitations
3.6 Stem Cell Transplantation, Procedure Volumes
3.7 Minitransplantation
3.8 Technological Aspects
	3.8.1 Companies and Products
		3.8.1.1 Baxter International
		3.8.1.2 CellPro
		3.8.1.3 Gambro
		3.8.1.4 Miltenyi Biotec/AmCell
		3.8.1.5 Market Analysis
		3.8.1.6 Market Forecast
	3.8.2 Stem Cell Expansion Ex Vivo
		3.8.2.1 Applications
		3.8.2.2 Culture Conditions
		3.8.2.3 Biotechnology
		3.8.2.4 Serum-Free Culture
		3.8.2.5 Bioreactors
			3.8.2.5.1 Flat Bed Perfusion Systems
			3.8.2.5.2 Hollow-Fiber Bioreactors
			3.8.2.5.3 Suspension Culture Systems
		3.8.2.6 Companies and Products
			3.8.2.6.1 Aastrom Biosciences
			3.8.2.6.2 Cytomatrix
			3.8.2.6.3 Tissue Therapeutics/Montec Research
			3.8.2.6.4 Viacell
		3.8.2.7 Market Analysis
	3.8.3 Umbilical Cord Blood
		3.8.3.1 Collection and Storage
		3.8.3.2 Private Versus Donor
		3.8.3.3 Private Storage
			3.8.3.3.1 Costs
		3.8.3.4 Market Analysis
		3.8.3.5 Market Forecast

Exhibit 3-1: Advantages and Disadvantages of Stem Cells, by Source
Exhibit 3-2: 2002, Registered Stem Cell Institutions
Exhibit 3-3: Malignant Disorders Treated Using Bone Marrow Transplantation
Exhibit 3-4: Advantages and Disadvantages of Bone Marrow Transplantation, by Type
Exhibit 3-5: 2002, Techniques Used for Purging Stem Cells of Tumor Cells
Exhibit 3-6: Bone Marrow Versus Peripheral Blood Stem Cell Transplantation
Exhibit 3-7: Indications for Allogenic and Autologous Stem Cell Therapy
Exhibit 3-8: Gene-Modified Stem Cell Therapy Applications for Genetic Disorders
Exhibit 3-9: 2001, Number of Patients on the National Patient Waiting List for Organ Transplantation
Exhibit 3-10: Stem Cell Transplantation, Procedure Volumes Forecast, by Type, 2001-2007
Exhibit 3-11: Stem Cell Transplantation, Procedure Volumes Forecast, by Disease, 2001-2007
Exhibit 3-12: 2002, Selected Stem Cell Extraction Devices
Exhibit 3-13: Stem Cell Extractors and Disposables, Market Forecast,  2001-2007
Exhibit 3-14: 2002, Aastrom Biosciences, Hematopoietic Stem Cell Product Pipeline
Exhibit 3-15: Advantages and Disadvantages of Using Umbilical Cord Blood as a Source Material for Stem Cells
Exhibit 3-16: 2001, Private Umbilical Cord Blood Banking Market, Share by Supplier
Exhibit 3-17: Umbilical Cord Blood, Unit Volumes Forecast, 2001-2007
Exhibit 3-18: Umbilical Cord Blood Products, Market Forecast, 2001-2007

4. COMPANY PROFILES

4.1 Aastrom Biosciences, Inc.
4.2 Abbott Laboratories, Inc.
4.3 Alliance Pharmaceutical Corporation
4.4 Amgen, Inc.
4.5 AstraZeneca Group
4.6 Aventis, Inc.
4.7 Baxter International, Inc.
4.8 Bayer AG
4.9 Biopure Corporation
4.10 Bristol-Myers Squibb Company
4.11 COBE Cardiovascular, Inc./SNIA Group
4.12 Fresenius HemoCare, Inc./Fresenius Medical Care AG
4.13 Haemonetics Corporation
4.14 Pharmacia Corporation
4.15 Wyeth, Inc.

COMPANY LISTING


COMPANIES COVERED:

  1. Aastrom Biosciences, Inc.
  2. Abbott Laboratories, Inc.
  3. Alliance Pharmaceutical Corporation
  4. Amgen, Inc.
  5. AstraZeneca Group
  6. Aventis, Inc.
  7. Baxter International, Inc.
  8. Bayer AG
  9. Biopure Corporation
  10. Bristol-Myers Squibb Company
  11. COBE Cardiovascular, Inc./SNIA Group
  12. Fresenius HemoCare, Inc./Fresenius Medical Care AG
  13. Haemonetics Corporation
  14. Pharmacia Corporation
Contact Us

Need help finding medtech research? Let us help you!